<DOC>
	<DOCNO>NCT01539915</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics pharmacodynamics BCT194 psoriatic patient well understand skin penetration topically apply BCT194 .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics BCT194 Psoriatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Inclusion criterion : Male patient post menopausal surgically sterile female patient age 18 75 year . Diagnosis stable plaque psoriasis ( without arthritis ) ; diagnose history psoriasis least 6 month prior screen Psoriatic plaque accessible microperfusion body site ( e.g . trunk ) convenient patient . Exclusion criterion : Currently nonplaque form psoriasis : erythrodermic , guttate , pustular . Currently druginduced psoriasis ( new onset exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) . Recent previous treatment antiTNFÎ± therapy ( biological therapy ) , immunosuppressive agent cyclosporine , mycophenolate , pimecrolimus , tacrolimus . Current sign symptom severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric , disease would make patient unsuitable trial . Presence major chronic inflammatory autoimmune disease like rheumatoid arthritis , spondyloarthropathy , inflammatory bowel disease systemic lupus erythematosus . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Stable plaque psoriasis</keyword>
	<keyword>lesion</keyword>
	<keyword>TNF-alpha</keyword>
	<keyword>BCT194</keyword>
</DOC>